StockWatch
·

Affle (India) Ltd Q1 FY27 Results

AFFLEQ1 FY27 Results
Filing
Result:Good· Market: FlatBroad basedCost led

Outlook: Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue747.16 Cr3.1%20.4%
Total Income772.21 Cr3.6%21.1%
Expenditure614.42 Cr2.8%20.8%
PBT157.79 Cr6.6%22.1%
Net Profit128.44 Cr7.5%21.7%
OPM22.43%0.18pp0.08pp
NPM16.63%0.60pp0.09pp
EPS9.137.3%21.4%
View full financials

IT-sector growth was healthy (revenue +20.4%, PAT +21.7% YoY) with flat margins exactly tracking management's reiterated 20% CAGR guidance rather than beating it, and underlying gross-margin pressure was masked by opex cuts rather than genuine margin expansion.

AFFLE · Q1 FY27 · THE VERDICT

20% Growth Intact, But Near-Term Catalysts Keep Slipping

Affle delivered on guidance (₹747 Cr revenue, ₹128 Cr PAT) with bottom-line leverage, but the market's day-1 -3.11% reaction signals disappointment: DM growth is softer than claimed, gross margin recovery is delayed again, and the larger M&A that was supposed to close in 2026 has slipped to early 2027.

17 Aug 2026 · 6 min read

The quarter in one move

Affle announced Q1 FY27 results on Saturday, August 08. The numbers looked solid on the surface — ₹747.2 Cr revenue (+20.4% YoY), ₹128.4 Cr net profit (+21.7%), EBITDA margin holding steady at 22.4%. The company had hit its 20% CAGR guidance, with PAT growing faster than revenue, a sign of cost discipline. And yet the stock fell 3.11% on day 1, recovering only partially by day 5 (+1.41%). That gap between the headline and the market's reaction is the real story of the quarter.

The disappointment was not about missing numbers — it was about missing momentum. Three near-term catalysts that management had signalled are now either pushed into the future, underperforming claims, or still unproven. That mismatch, plus FII trimming positions (−1.28pp to 15.38%), tells you the street was pricing in step-change progress on this call and didn't get it.

Revenue growth YoY

20.4%

on guidance (20% CAGR); sequential +3.1% — slowest in 14 quarters

PAT growth YoY

21.7%

outpacing revenue; PBT +22.1% shows operating leverage

EBITDA margin

22.4%

flat vs Q4 FY26 and prior quarters; no recovery visible

DM revenue growth

20.7%

headline; ex-currency likely 11-12% per analyst; management silent on gap

Where the softness lives

On the face of it, delivering 20.4% revenue and 21.7% PAT sounds like firing on all cylinders. But the quarter masks three underlying tensions that the market immediately priced in.

Management's key claims: what holds up, what doesn't

14 consecutive quarters of sequential growth; ₹747 Cr is highest ever quarterly revenue

Supported: ₹747.2 Cr is a record. But sequential +3.1% is the lowest in that 14-quarter streak, not the highest.

Supported but incomplete

Developed Markets 20.7% YoY growth, strategic focus for 20%+ sustained growth

Headline 20.7% is accurate. But analyst noted ex-currency DM growth likely 11-12%; management did not dispute, only defended the addressable market thesis.

Overstated (headline masks weakness ex-currency)

Gross margin improvement expected within this financial year (FY27)

Inventory/data costs at 63.2% of revenue, flat QoQ. Prior call (FY26): 'improvements expected in about a year' (implying Q2–Q3 FY27). Recovery now conditional on DM scale and currency normalization; timeline ambiguous.

Supported in intent, slipped in timeline

Larger M&A to close early 2027, accretive and sustaining 20%+ combined growth

Prior call (FY26): 'meaningful acquisition possible in calendar year 2026.' Now: in due diligence, targeting 'early 2027' close. No deal size, margin profile, or contractual commitment disclosed.

Unverified; timing slipped 6 months

Developed Markets: the headline-vs-reality gap

Affle generates 27.8% of revenue from Developed Markets (≈₹208 Cr, +20.7% YoY). Management touts this as proof that its model scales in mature markets and justifies the long-term 20%+ DM growth narrative underpinning the 10x vision. But in the Q&A, an analyst noted that ex-currency DM growth is likely 11–12%, not 20%. Management did not dispute the math, only reframed the opportunity (addressable market is large, small base, differentiation story). That silence is the tell: headline growth is being inflated by currency tailwinds, and underlying momentum is softer.

This matters because if DM mix continues to rise (now 28% of revenue) and ex-currency growth stays at 11-12%, overall company growth will compress below the 20% guidance unless the remaining 72% of Emerging Markets accelerates faster. AdColony (acquired this quarter) and the larger M&A are supposed to fix this by unlocking DM publisher scale and premium CPCU rates. Both are still unproven.

Gross margin: recovery pushed further out

In the Q4 FY26 earnings call, management said gross margin would improve "in about a year." That timeline pointed to Q2–Q3 FY27. Instead, Q1 FY27 shows inventory/data costs at 63.2% of revenue, unchanged from Q4. Management attributes this to currency pass-through to clients and strategic investments in verticalization, with recovery conditional on DM scale and AdColony integration. In other words: the goalposts have moved, and the timeline is now vague ("within this FY") and contingent.

EBITDA margin held steady at 22.4%, so operating leverage is masking the gross margin compression. But if currency normalizes or competitive pressure rises, that offset disappears. The risk is that margin expansion doesn't show until H2 FY27 at best, further delaying the profitability inflection the market is pricing in.

What changed on this call

Shifts vs. prior quarter's signalling
  • AdColony acquisition completed (new positive) — unlocks 100k app publishers, 500M connected devices in Developed Markets (organic, by end of FY27); but execution proof still pending

  • Gross margin recovery timeline slipped from 'about 1 year' (prior call) to 'within this FY pending DM scale' (this call); no recovery visible yet

  • Larger M&A closure pushed from 'possible in calendar 2026' to 'targeting early 2027'; now in due diligence with no size or deal profile disclosed

  • Direct advertiser revenue mix rose to 79% (from 74% FY26); management says no strategic preference, but customer concentration and segment-specific headwinds (RMG down, FinTech pressured) are now more evident

How the street is positioned

Price action: The result was announced on Saturday, August 08. The stock fell 3.11% on day 1 (pre-announcement close ₹1645.6), recovered to +1.66% by day 3, and settled at +1.41% by day 5 (current price ₹1668.8). This is a "initial disappointment, partial recovery" pattern — not a washout, not a rally, just a re-rating down on softer near-term catalysts.

Valuation context: Affle trades at ₹1668.8, down 14.87% from its all-time high (₹1960.2) but above its 20-day, 50-day, and 200-day simple moving averages (₹1602, ₹1524.7, ₹1563.99 respectively). The stock is in a "consolidation" zone — support is holding, but upside momentum has stalled. Trend rating is NEUTRAL. Volume is DECREASING, a sign that neither strong buyers nor strong sellers are in control; the market is waiting for proof.

Institutional flows: FII ownership fell to 15.38% (−1.28pp QoQ), the lowest in at least two years, suggesting smart money has been rotating out or taking profits near the highs. Domestic institutional investors (DII) added slightly to 18.78% (+0.88pp), indicating some local buying on the dip. Promoters remain steady at 54.91%. The FII outflow is the key signal: international money is skeptical on near-term execution and may be rotating to other India EM stories or de-risking exposure ahead of currency volatility or rate signals.

The street's reading is clear: Affle is hitting its 20% organic growth target, but the step-change narrative (to 25%+ via DM acceleration + M&A) is not materializing on this call. Near-term catalysts (margin recovery, M&A close, DM acceleration) are all being pushed into the future or underperforming headline claims. Until one of these inflects positively (Q2 AdColony ramp, Q3 margin recovery, early 2027 M&A closure), the stock is fairly valued to slightly overvalued, with upside contingent on proof of re-acceleration.

The bull-bear ledger

Positives
  • 14 consecutive quarters of sequential revenue growth; 20.4% YoY delivery on 20% CAGR guidance — execution track record is solid

  • PAT growth +21.7% > revenue growth +20.4%; PBT grew 22.1% — operating leverage is real, cost discipline intact despite scale

  • Strategic positioning defensible: verticalization (E, F, H strong), AI/agentic intelligence (300+ patent claims), consumer platform differentiation in a commoditized AdTech market

  • AdColony acquisition completed — unlocks brand, SDK, premium publisher ecosystem in Developed Markets organically; 100k app target this year if execution on track

Negatives
  • DM headline growth 20.7% masks ex-currency weakness (~11-12%); if DM mix rises and ex-currency growth stays flat, overall growth compresses below 20% guidance

  • Sequential revenue growth +3.1% is the lowest in 14 quarters; seasonal Q1 headwind or signal of structural slowdown?

  • Gross margin compression not recovering; timeline from prior call ('about 1 year') has now slipped, and recovery is conditional on unproven DM scale and AdColony ramp

  • Larger M&A slipped 6 months (CY2026 → early 2027) and remains in due diligence; no deal size, margin profile, or contractual commitment disclosed; history of timing misses

  • Direct advertiser concentration at 79% (up from 74% FY26); RMG and FinTech segments pressured by regulatory/macro headwinds; recovery timeline unspecified

  • FII ownership trimmed to 15.38% (−1.28pp), suggesting smart money rotation or profit-taking; international skepticism on near-term catalysts

  • OCF to PAT ratio weak at 41% (vs 110% prior year); though management expects normalization by Q3, working capital timing and collection risk need monitoring

Risks, ranked by how much they should concern a holder

The most material risks to near-term performance

Developed Markets growth ex-currency stays at 11-12%, not 20%

HIGH

If DM mix deepens and underlying growth doesn't accelerate, overall company growth compresses below guidance. Both AdColony and larger M&A depend on DM re-acceleration; if DM is the problem, not the solution, the 10x thesis collapses.

Larger M&A timing slips past early 2027 or deal fails to close accretive

HIGH

M&A is critical to reaching 25-26% CAGR required for 10x in 5 years. If deal timing slips further (history suggests it might) or if accretion misses, the combined entity growth target (20%+ claimed) becomes unachievable. Conviction in step-change narrative erodes.

Gross margin compression persists; recovery delayed to H2 FY27 or later

MEDIUM

EBITDA margin expansion is being masked by operating leverage now. If margin recovery doesn't show by Q2-Q3, and if currency normalizes or competitive pressure rises, bottom-line profitability inflection is pushed into FY28. Valuation assumes margin recovery; if it doesn't happen, multiple compression likely.

Direct advertiser concentration (79%) and segment headwinds (RMG, FinTech) compound

MEDIUM

RMG segment is in recovery phase; FinTech pressured. If these headwinds persist and direct mix continues to rise, revenue growth becomes more volatile and dependent on a smaller customer base. Single large advertiser loss would sting given concentration.

Bobble impairment (₹136 Cr) — appeal outcome uncertain, write-off risk

MEDIUM

Bobble company is bankrupt. Management deferred impairment pending NCLT appeal. If appeal fails, ₹136 Cr write-off is likely, compressing FY27 profitability and creating near-term earnings surprise to the downside.

AdColony SDK integration misses 100k app target or margin uplift doesn't materialize

MEDIUM

AdColony is the near-term execution proof point for DM scale. If app integrations stall, publisher activation misses, or margin profile doesn't improve, confidence in DM strategy erodes further. Likely to show up in Q2-Q3 guidance.

The debate

What to watch next

The concrete proof points due in the next 2–3 quarters
  • 1 · Q2 FY27 (Sep 2026) — AdColony SDK ramp

    How many apps have integrated the AdColony SDK? Are publisher activation metrics trending toward the 100k app target? Is there evidence of higher CPCU rates or margin uplift in DM channels? This is the organic unlock story; execution here validates the DM thesis.

  • 2 · Q3 FY27 (Dec 2026) — Margin recovery signal

    Festive quarter (typically strong in India) should show whether gross margin compression is reversing. If inventory/data costs fall as % of revenue or if currency headwinds ease, this signals the recovery timeline is back on track. OCF to PAT ratio should normalize to 80-85% (from 41% Q1), confirming working capital timing was the issue.

  • 3 · Early 2027 — Larger M&A announcement/closure

    What's the target? What's the size and deal multiple? What's the margin profile post-integration? Can management credibly commit to combined entity growing 20%+ and being EPS-accretive? This is the key inflection point for the 10x narrative; if it slips past early 2027 or the deal is smaller/less accretive than implied, conviction erodes significantly.

  • 4 · NCLT appeal outcome (Bobble)

    Will courts rule in Affle's favor and grant inspection rights? Or will the impairment testing be deferred further? A ₹136 Cr write-off would compress FY27 net profit by ~10.6%, creating a near-term earnings surprise. A favorable ruling would de-risk the balance sheet and open strategic optionality.

  • 5 · DM ex-currency growth validation

    In Q2-Q3 call, push for specific disclosures: DM growth ex-currency, DM CPCU rates (absolute and vs. EM), DM customer acquisition cost trends. If underlying DM momentum stays at 11-12%, the market will re-rate downward; if it accelerates to 15%+, the bull case gains traction.

What's the number to track?

Reported revenue growth will stay at ~20%, buttressed by guidance and the long streak of sequential growth. But the real metric is sequential revenue growth ex-M&A. If Q2 and Q3 show sequential growth below 4-5%, that signals underlying momentum (organic) is slowing, and the 20% CAGR is being propped up by base effects or one-time items, not genuine acceleration. If sequential growth stays above 5% and margins show recovery in Q3, the narrative holds. If sequential drops below 3%, watch out — the slowdown is real.

The closing read

Affle is delivering steady execution: 20% organic growth on track, bottom-line leverage intact, strategic positioning sound. But the near-term momentum narrative has stalled. Gross margin recovery was promised 'in about a year' and is now delayed; the larger M&A that was supposed to close in 2026 is now targeted for early 2027; and Developed Markets growth, the linchpin of the step-change story, is softer than headline claims suggest.

The market's initial -3.11% reaction and FII rotation (−1.28pp) signal that the street expected inflection proof on this call — a sign of margin recovery, an M&A announcement, or an acceleration in DM growth ex-currency. It didn't get any of those. The stock has recovered partially, but trend is neutral and volume is declining, a classic 'wait and see' posture.

Affle remains a high-quality 20% organic growth franchise with defensible moat. But upside from here requires proof that the company can re-accelerate to 25%+ (via Developed Markets + large M&A), not just sustain 20%. That proof is due in Q2–Q3 FY27 and early 2027. Until it arrives, hold at ₹1668.8. The single number to track: is sequential revenue growth holding above 5%, or has it slipped structurally below 4%? That will tell you if 20% is a true narrative or a fading trend.

Informational and educational content only. Not investment advice.

Affle (India) Ltd (AFFLE) Q1 FY27 Results, Transcript & Analysis — StockWatch